| Autor: |
Cooper, Keith, Picot, Joanna, Onyimadu, Oluchukwu, Shepherd, Jonathan, Lord, Joanne, Scott, David A. |
| Jazyk: |
angličtina |
| Rok vydání: |
2018 |
| Předmět: |
|
| Popis: |
This report is a critique of the company’s submission (CS) to NICE from Bayer on the clinical effectiveness and cost effectiveness of rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease. It identifies the strengths and weakness of the CS. Clinical experts were consulted to advise the ERG and to help inform this review. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
